Human Papillomavirus Genotype Detection in Recurrent Respiratory Papillomatosis (RRP) in Colombia

ABSTRACT: Background: Knowledge on human papillomavirus (HPV) genotype distribution in recurrent respiratory papillomatosis (RRP) is essential to assess the impact of HPV vaccine. It is provided information for Colombia. Methods: In all, 189 RRP primary cases diagnosed between 1985 and 2009 were ide...

Full description

Autores:
Sánchez Vásquez, Gloria
Jaramillo Velásquez, Roberto
Cuello Bueno, Gustavo Adolfo
Quintero Martínez, Katherine
Baena Zapata, Armando
O’Byrne Olano, Adriana
Reyes Solarte, Antonio José
Santamaría Herrera, Consuelo
Cuello Bueno, Harold Daniel
Arrunátegui Ramírez, Ana María
Cortez, Armando
Osorio Sandoval, Germán
Reina Reina, Julio Cesar
Quint, Wim GV
Muñoz Calero, Nubia
Tipo de recurso:
Article of investigation
Fecha de publicación:
2013
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/33738
Acceso en línea:
https://hdl.handle.net/10495/33738
https://onlinelibrary.wiley.com/doi/10.1002/hed.22953
Palabra clave:
Human papillomavirus 11
Papillomavirus Humano 11
Papilloma
Papiloma
Human papillomavirus 6
Papillomavirus Humano 6
Respiratory Tract Infections
Infecciones del Sistema Respiratorio
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Description
Summary:ABSTRACT: Background: Knowledge on human papillomavirus (HPV) genotype distribution in recurrent respiratory papillomatosis (RRP) is essential to assess the impact of HPV vaccine. It is provided information for Colombia. Methods: In all, 189 RRP primary cases diagnosed between 1985 and 2009 were identified from 5 pathology laboratories of Cali and Medellin, Colombia. HPV DNA testing in 129 cases that fulfilled inclusion criteria (available paraffin blocks, amplifiable DNA, and confirmed histologic diagnosis of RRP) was performed by the SPF-10/LiPA25 assay (version 1). Results: Of all cases 36.1% were juvenile (<12 years old) and a majority of adults were males (p = .09); 95% of cases were HPV positive. HPV 6, 11, and 16 contributed to 69%, 27.1%, and 7.8% of all HPV positive cases. Twelve cases (9.3%) showed multiple infections; 8 of these were HPV 6 or 11 positive. Conclusions: HPV prophylactic vaccine including HPV 6 and 11 may have a major impact against RRP.